company background image
F6T logo

Fate Therapeutics DB:F6T Stock Report

Last Price

€1.58

Market Cap

€183.4m

7D

-11.3%

1Y

-47.8%

Updated

22 Dec, 2024

Data

Company Financials +

My Notes

Capture your thoughts, links and company narrative

Fate Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Fate Therapeutics
Historical stock prices
Current Share PriceUS$1.58
52 Week HighUS$7.59
52 Week LowUS$1.58
Beta1.93
1 Month Change-27.60%
3 Month Change-54.27%
1 Year Change-47.82%
3 Year Change-97.18%
5 Year Change-91.18%
Change since IPO-68.84%

Recent News & Updates

Recent updates

Shareholder Returns

F6TDE BiotechsDE Market
7D-11.3%-2.9%-2.6%
1Y-47.8%-14.7%6.9%

Return vs Industry: F6T underperformed the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: F6T underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is F6T's price volatile compared to industry and market?
F6T volatility
F6T Average Weekly Movement14.5%
Biotechs Industry Average Movement6.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: F6T's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: F6T's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2007181J. Wolchkowww.fatetherapeutics.com

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors.

Fate Therapeutics, Inc. Fundamentals Summary

How do Fate Therapeutics's earnings and revenue compare to its market cap?
F6T fundamental statistics
Market cap€183.38m
Earnings (TTM)-€170.82m
Revenue (TTM)€12.89m

14.2x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
F6T income statement (TTM)
RevenueUS$13.45m
Cost of RevenueUS$122.31m
Gross Profit-US$108.86m
Other ExpensesUS$69.37m
Earnings-US$178.23m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.56
Gross Margin-809.56%
Net Profit Margin-1,325.43%
Debt/Equity Ratio0%

How did F6T perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 21:11
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fate Therapeutics, Inc. is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Peter LawsonBarclays
Etzer DaroutBMO Capital Markets Equity Research